Kontracept

Quick links to important sections

Kontracept

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kontracept

Kontracept is defined as a Combined Oral Contraceptive Pill (COCP), functioning as a prescriptive, synthetic hormonal preparation used primarily for pregnancy prevention in women of reproductive age. It is delivered as oral tablets and is classified within the Progestogen and Estrogen group. This combination product utilizes two complementary active ingredients to provide systemic action via the oral route of administration.

Property Description
Active Ingredients Ethinyl Estradiol, Gestodene
Form Oral tablets (Combined Oral Contraceptive Pill)
Pharmacological Class Progestogen and Estrogen (Combined Hormonal Contraceptive)
Common Use Prevention of pregnancy (Contraception)
Origin Synthetic

What Type of Medicine is Kontracept? (Identity and Classification)

Kontracept belongs to the combined hormonal contraceptive class, which is distinguished by the simultaneous presence of both a synthetic estrogen and a synthetic progestin. This medicinal entity is a combination product, contrasting with single-ingredient hormonal methods that rely only on a progestogen. The combination preparation reflects a strategy in pharmaceutical science aimed at balancing hormonal activity for robust cycle control. As a COCP, this type of medication is recognized for high effectiveness when adherence is maintained. This affirms that the medicine offers women a dependable, non-surgical option for controlling fertility.

Composition and Origin: Is Kontracept Natural or Synthetic? (The Active Ingredients)

Kontracept contains two synthetic active ingredients: Ethinyl Estradiol and Gestodene. Ethinyl Estradiol serves as the synthetic estrogen component, while Gestodene is the synthetic progestin component, typically categorized as a third-generation progestin. This formulation is a key differentiating factor, as Gestodene is structurally distinct from earlier progestin generations. Gestodene is a potent progestogen with high bioavailability when administered orally. These synthetic components are absorbed and utilized by the body to execute their hormonal function. These active substances are precisely formulated within an inert oral excipient matrix to ensure the stability and controlled delivery necessary for the tablet form.

Primary Purpose of Kontracept (General Benefit)

The singular purpose of Kontracept is the prevention of pregnancy, achieved through its influence on the female reproductive system. It is used in a typical scenario where a woman of reproductive age seeks a reliable, prescribed method to manage her fertility. The combined action of the synthetic estrogen and progestin on the body's hormonal environment acts to inhibit the primary biological events necessary for conception. By modulating the natural reproductive cycle, Kontracept offers a highly reliable method of contraception for adult women who choose this oral tablet delivery system.

Regulatory References

  1. Combined Oral Contraception
  2. Combined oral contraception
  3. clinically recognized
  4. third-generation progestin

What side effects are possible with Kontracept?

Possible Side Effects and Safety Information

The safety profile of Kontracept, a combined hormonal contraceptive, is documented by government regulatory agencies based on clinical trial data and post-market surveillance. The adverse reactions are formally classified by frequency and the body system affected.

Frequency-Classified Adverse Reactions

Side effects are categorized based on their documented occurrence rates:

  • Very Common (Affecting ge 1 in 10 users): Headache, breakthrough bleeding, or spotting.
  • Common (Affecting 1 to 10 in 100 users): Nausea, mood changes, breast tenderness or pain, weight gain, and changes in menstrual bleeding patterns.
  • Uncommon (Affecting 1 to 10 in 1,000 users): Vomiting, fluid retention, changes in appetite, and skin rash.
  • Rare (Affecting 1 to 10 in 10,000 users): Venous or arterial blood clots (thromboembolic events) and hypersensitivity reactions.

Serious Safety Risks

Official regulatory documents emphasize the risk of thromboembolism (blood clots in veins or arteries) as a rare but serious safety concern. This includes the potential for deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction (heart attack). These risks are considered highest during the first year of use or upon restarting the medicine after a break of four weeks or more.

Contraindications and Limitations

Kontracept is contraindicated (must not be used) if certain medical conditions are present, as use would significantly elevate safety risks. These include a personal history of, or current, venous or arterial thrombotic events, presence of thrombogenic inherited mutations, severe or uncontrolled high blood pressure, migraine with focal aura, or known/suspected hormone-sensitive malignancies (e.g., breast cancer). Caution and monitoring are required for specific populations, such as women with diabetes or severe hypertriglyceridemia.

Overdose and Emergency Response

Overdosing on combined oral contraceptives like Kontracept is rarely life-threatening due to the low toxicity of the hormonal ingredients. However, taking a large number of pills at once may lead to uncomfortable but generally temporary symptoms.

Symptoms of Overdose

The most common symptoms associated with a hormonal overdose include:

  • Nausea and/or vomiting
  • Breast tenderness
  • Light to heavy vaginal bleeding (withdrawal bleeding, which may occur 2–7 days later)
  • Headache

These symptoms typically resolve on their own as the body processes the excess hormones and usually do not require extensive medical intervention.

When to Seek Help

Immediately contact a healthcare provider or emergency services if you experience any of the following severe symptoms, as they may indicate a more serious condition:

Symptom Category Indicators for Emergency Help
Cardiovascular/Respiratory Chest pain, shortness of breath, unexplained coughing up blood, sudden, severe pain, swelling, or warmth in the leg (potential blood clot).
Neurological Sudden, severe headache unlike any experienced before, sudden changes in vision, loss of consciousness, or fainting.
Other Severe Reactions Uncontrolled, persistent vomiting, or signs of a severe allergic reaction (e.g., facial swelling, hives).

If you have taken a large amount of Kontracept and are concerned, or if you are experiencing distress, contact a poison control center or healthcare professional for personalized guidance, even if symptoms are mild. If the overdose was intentional, seek immediate crisis and medical support.

Therapeutic Uses of Kontracept

Kontracept is commonly used to prevent pregnancy, and may also be applied to manage several symptoms related to hormonal cycles. The primary therapeutic domains of use are contraception and the supportive management of menstrual cycle-related discomforts.

As a combined hormonal contraceptive, it is used to prevent pregnancy and may also be used to address other conditions such as acne, painful periods (dysmenorrhea), and heavy or irregular menstruation.

The medication is commonly used across conditions characterized by periods of heightened symptoms, including the prevention of pregnancy, the management of heavy and painful periods, and the addressing of hormone-related acne. By providing support that helps ease the overall symptom load, Kontracept assists with maintaining functional stability.

“This approach supports patients during episodes of heightened discomfort and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Relief for Heavy, Painful, or Irregular Periods

Kontracept is applied in settings marked by temporary physiological imbalance to help manage symptoms related to a disruptive menstrual cycle. It may assist with easing the impact of symptoms that interfere with routine activities, offering a supportive therapeutic benefit across symptomatic domains.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Kontracept — Official Regulatory Information

The eligibility profile for Kontracept, a combined oral contraceptive pill, is defined by strict exclusionary criteria documented in government regulatory sources, such as the FDA and EMA.

Eligibility Scope Regulatory Rule (Official Status)
Populations Allowed Females of reproductive potential (post-menarche, pre-menopause).
Populations Contraindicated Females over age 35 who smoke.
  • Individuals with history of venous or arterial thrombosis (DVT, PE, Stroke, Myocardial Infarction).
  • Females with Migraine with aura or known thrombogenic mutations.
  • Patients with Uncontrolled Hypertension or Diabetes with vascular disease.
  • Patients with Liver tumors, severe cirrhosis, or current Breast Cancer. | | Age-Related Rules | Not indicated before menarche or for postmenopausal women. | | Pregnancy Status | Contraindicated during known or suspected pregnancy. | | Lactation Status | Not recommended for breastfeeding mothers (may affect milk supply). |

Eligibility Classifications (High-Level)

Classification Regulatory Basis
Severity Contraindicated (absolute prohibition) and Not Recommended (conditional prohibition/strong caution).
Context Eligibility is primarily constrained by Thrombotic Risk and Hormone-Sensitive Cancer Risk.

Connection to the overall eligibility profile Official regulatory documents define who can and cannot use this medicine by establishing strict exclusionary criteria, known as contraindications. These criteria prohibit use for females with specific high-risk health states, particularly those related to thromboembolism and estrogen-sensitive malignancy. Use is permitted only for females of reproductive potential who do not possess these documented high-risk characteristics, with explicit restrictions noted for age and postpartum status.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for Kontracept (Ethinyl Estradiol/Gestodene) based on regulatory information.

Formal Restrictions and Contraindicated Combinations

Co-administration of Kontracept is formally contraindicated with the specific Hepatitis C direct-acting antiviral (DAA) regimen of Ombitasvir/Paritaprevir/Ritonavir, with or without Dasabuvir. Regulatory requirements mandate that patients must switch to an alternative contraceptive method prior to initiating this DAA therapy, and Kontracept can only be restarted 2 weeks following the completion of the antiviral treatment.

Exposure-Altering Interactions

Medicines and products that induce hepatic enzymes can reduce the concentration of Kontracept’s hormonal components, potentially compromising efficacy. These substances include Rifampin, Griseofulvin, and the herbal product St. John’s Wort.

Conversely, Kontracept is documented to increase the plasma exposure of certain other drugs, such as Tizanidine, by inhibiting its clearance. Additionally, Etoricoxib is noted to increase the exposure to the Ethinyl Estradiol component of Kontracept.

Interaction Type Interacting Substance Resulting Official Caution
Reduced COCP Exposure Enzyme Inducers (e.g., Rifampin, St. John's Wort) Decreased contraceptive efficacy
Increased COCP Exposure Etoricoxib Requires careful assessment of Ethinyl Estradiol dose
Increased Other Drug Exposure Tizanidine Increased plasma concentration of Tizanidine

Population-Specific Notes

Official documents note that individuals with impaired liver function may experience reduced clearance of the steroid hormones in Kontracept, which is a factor in assessing potential interaction severity.

Mechanism of Action

The mechanism of Kontracept, containing Ethinyl Estradiol and Gestodene, is defined by their agonism at Estrogen Receptors (ER) and Progesterone Receptors (PR). This binding primarily occurs within the hypothalamus and pituitary gland, establishing a constant, non-fluctuating negative feedback signal on the Hypothalamic-Pituitary-Ovarian (HPO) axis. This signal suppresses the release of FSH and LH. The resulting systemic modulation prevents the necessary LH surge, leading directly to the physiological effect of anovulation (cessation of egg release).

Simultaneously, Gestodene exerts a critical peripheral mechanism by acting on Progesterone Receptors in the cervix and endometrium. This action induces changes in cervical gland secretion, causing the cervical mucus to become highly viscous, which impedes sperm motility and transport. Furthermore, the hormonal state prevents the normal cyclical buildup of the uterine lining, resulting in endometrial atrophy that induces structural modification of the tissue.

Dosage and Administration Information

How Kontracept is Used: Official Administration Guidelines

Kontracept is a Combined Oral Contraceptive Pill (COCP) administered according to a precise, continuous, cyclic regimen defined in official prescribing information. The instructions dictate the route, frequency, and duration of the course necessary for standardized use.


Official Dosing and Route of Administration

The approved route of administration for Kontracept is oral, delivered as tablets to be swallowed whole. The dosing schedule is one tablet per day, consistently maintaining a specific microgram strength in the active tablets of Gestodene 75 mu g and Ethinyl Estradiol 30 mu g. This daily dose is fixed and is not subject to titration.


Cyclic Regimen and Daily Timing

Use follows a 28-day cycle repeated continuously for long-term administration. The standard cycle involves taking one active tablet daily for 21 consecutive days, followed by a 7-day tablet-free interval (or 7 days of placebo tablets). A new cycle must begin immediately after the 7-day interval is complete, regardless of the presence of bleeding. To ensure consistent hormonal levels, the tablet must be taken at approximately the same time each day, and the order printed on the blister pack must be followed.


Procedural Instructions and Handling Missed Doses

When initiating treatment, a Day 1 Start (first day of menses) is a common option. If starting later, or following an interruption in the schedule, the official instructions dictate the temporary use of a non-hormonal back-up method for the first 7 days of consecutive tablet-taking. Official instructions also detail the specific procedures for handling missed doses: if a dose is missed by more than 12 hours, an immediate action is required, along with the mandatory use of the back-up method for the next 7 days.

Recent Clinical Evidence

Ź Evidence for Preventing Pregnancy (Contraception)

Research exploring Kontracept and the class of combined oral contraceptives (COCs) primarily relies on systematic reviews and large-scale observational studies that monitor many women over time. These studies were evaluated in research examining the prevention of pregnancy, a key outcome related to systemic or functional imbalance. Researchers monitored the rate of pregnancy occurrence, often measured using the Pearl Index, a finding that contributes to the broader evidence landscape for this method. They also monitored how consistently patients continued to use the medication and the patterns of menstrual cycle regularity.

Findings describe patterns observed in studies reporting that the outcomes measured included the reported pregnancy rate observed in the studied populations. However, studies also report how real-world use introduces variables like missed doses. Adherence was noted as a significant factor in the differences between ideal and typical use reporting. What remains uncertain is the full extent of reported outcomes when compared across various low-dose formulations, as differences in reported outcomes are often difficult to confirm with precision in head-to-head clinical trials. Data for certain subgroups, such as women with significant variations in body weight, remain limited in the available research.


ŷ Evidence for Managing Menstrual Cycle-Related Discomforts

Kontracept was studied for its use in managing symptoms associated with the menstrual cycle, such as painful periods (dysmenorrhea). Research has explored outcomes related to physical discomfort through randomized controlled trials (RCTs). Findings describe patterns observed in studies, reporting changes in pain scores in the women receiving hormonal treatment compared to those receiving placebo. The body of evidence remains limited when assessing the long-term management of these discomforts, as follow-up durations were limited in many of the relevant RCTs, and certainty varies across studies due to differences in how pain was measured.


⎗ Research Gaps and What Remains Uncertain

The overall level of evidence certainty varies across studies. The main gaps and limitations in the evidence landscape include: comparative evidence is lacking between specific formulations and placebo for secondary uses; sample sizes were modest in some comparative trials; and long-term effects are not fully established for the management of acne and menstrual pain. Research does not determine whether an individual will respond similarly or how they will tolerate the medication.

Frequently Asked Questions (FAQ)

Common questions about Kontracept (FAQ)


Q: How quickly does Kontracept start working to prevent pregnancy?

A: If you begin taking Kontracept on the first day of your menstrual period (Day 1 Start), the official product information indicates that protection is generally established immediately. If you start taking the tablets between Day 2 and Day 5, however, use of a non-hormonal back-up method of contraception, such as condoms, is necessary for the first 7 consecutive days of active tablet-taking.


Q: Does Kontracept commonly cause weight gain?

A: According to the official regulatory documents, weight gain is listed as a Common adverse reaction. This means that based on clinical trial data, this side effect may be experienced by between 1 and 10 out of every 100 users.


Q: Why do some people feel nauseous when they first start Kontracept?

A: Nausea is a Common side effect associated with Kontracept use. While the regulatory label does not explain the exact cause, this effect is often associated with the body adjusting to the medication, and gastrointestinal disturbances are frequently reported in the initial phase of use.


Q: Does Kontracept also help with conditions other than pregnancy prevention?

A: The primary and officially approved use of Kontracept is for oral contraception (pregnancy prevention). Research has explored the use of combined hormonal contraceptives like Kontracept for secondary benefits, such as relieving the symptoms of dysmenorrhea (painful periods), but this is not its main regulated indication.


Q: Why is Kontracept sometimes prescribed for acne?

A: Combined oral contraceptives (COCs) are sometimes used for their potential to improve acne. Official regulatory information indicates that the progestin component, Gestodene, has a low potential for androgenic effects, a characteristic that is generally beneficial when managing hormone-related skin conditions.


Q: How long after stopping Kontracept can you get pregnant?

A: Official regulatory data may show temporary changes to fertility after discontinuing use. However, the ability to become pregnant generally returns, though the specific time frame for the return of normal fertility varies greatly among individuals.


Q: Can women over 40 use Kontracept?

A: Use is contraindicated (not permitted) for women over 35 who smoke due to significantly increased cardiovascular risks. For non-smoking women over 40, the decision requires careful medical assessment of all individual cardiovascular risk factors, as age is a factor in assessing overall risk.


Q: Does Kontracept affect libido or sex drive?

A: Mood changes are explicitly listed in official documents as a Common side effect of Kontracept. While the term 'libido' (sex drive) is not always detailed in the side-effect list, changes in sexual desire are sometimes reported in clinical experience related to hormonal contraceptives.


Q: What is the typical duration of effect for Kontracept?

A: The continuous contraceptive effect is maintained by taking one tablet at approximately the same time each day. This daily timing ensures that the active components, such as Gestodene, with an elimination half-life of about 12 to 15 hours, remain at effective concentrations in the body.


Q: Is feeling moody or having mood swings a common side effect of Kontracept?

A: Yes, mood changes are explicitly listed as a Common adverse reaction in the official product information. This means that changes in mood may be observed in up to 10 out of every 100 users.


Q: Can Kontracept affect your period, like making it lighter or heavier?

A: Official information indicates that changes in menstrual bleeding patterns are a Common adverse reaction. These changes can include experiencing either a lighter or, less commonly, a heavier period than usual.


Q: Do you get withdrawal bleeding when you stop taking Kontracept?

A: Yes, a withdrawal bleeding is expected to occur during the 7-day tablet-free interval (or placebo days) defined in the product’s cycle. This bleeding typically begins on the second or third day after the last active tablet is taken.


Q: What happens if you miss one dose of Kontracept?

A: If you miss an active tablet dose by less than 12 hours, official regulatory guidance states that contraceptive protection is not reduced. Regulatory guidelines suggest taking the missed tablet as soon as it is remembered and continuing with the rest of the pack at the usual time.


Q: What should I do if I accidentally take two Kontracept pills in one day?

A: No severe adverse effects are usually reported from an overdose of combined oral contraceptives. The regulatory advice for managing missed doses suggests taking the last missed tablet immediately, even if this means taking two tablets at the same time (i.e., in one day), and this advice generally applies to accidentally taking two pills.


Q: Is the effectiveness of Kontracept reduced if you are sick with vomiting or diarrhea?

A: Yes, the effectiveness of the tablet may be compromised. If vomiting or severe diarrhea occurs within 3–4 hours after taking a tablet, the absorption of the hormones may be incomplete. Regulatory guidelines advise treating this situation the same way a missed dose is handled.


Q: Is it normal to have spotting during the first month on Kontracept?

A: Breakthrough bleeding, or spotting is listed as a Very Common adverse reaction, meaning it affects ge 1 in 10 users. It is a frequent occurrence, particularly during the initial months as the body adjusts to the hormonal changes.


Q: Does Kontracept protect against sexually transmitted infections (STIs)?

A: No. Official patient information states that Kontracept, like all combined oral contraceptives, is not a barrier against HIV/AIDS or other sexually transmitted diseases (STDs).


Q: Can Kontracept be used by women with a history of migraines?

A: The use of Kontracept is contraindicated (not permitted) if a woman has a history of, or currently experiences, migraine with focal aura due to an elevated risk of stroke. For migraines without aura, the use requires a careful medical assessment of all associated risk factors.


Q: Is Kontracept a good option for people who smoke?

A: Cigarette smoking is associated with an increased risk of serious cardiovascular side effects like blood clots. Use is not permitted for women over 35 who smoke. For all users, smoking should be discussed with a healthcare provider.


Q: How is Kontracept typically stored at home?

A: Kontracept is required to be stored at a temperature not exceeding 25 C and kept protected from light to maintain its stability. It should be stored out of the sight and reach of children.


Q: Does Kontracept make you more sensitive to the sun?

A: Regulatory documents advise that if a user has a history of chloasma (skin discoloration/dark patches on the face), they should avoid direct exposure to sunlight or ultraviolet light while using Kontracept, as it may worsen this condition.


Q: Is it okay to switch from another birth control brand directly to Kontracept?

A: Yes, regulatory guidance outlines the process for switching between combined oral contraceptives (COCs). The first Kontracept tablet should typically be taken on the day after the last active tablet of the previous COC, or at the latest, on the day following the usual tablet-free interval.


Q: Can Kontracept cause headaches, or make existing headaches worse?

A: Headache is listed as a Very Common adverse reaction. Regulatory information also notes that the sudden onset of severe, recurrent, or unusually persistent headaches can be a warning sign of a serious condition, such as a blood clot, that warrants immediate medical help.


Q: Is it common to have breast tenderness when starting Kontracept?

A: Breast tenderness or pain is listed as a Common adverse reaction. These effects are often reported during the initial phase of use as the body adjusts to the hormones.


Q: Are there any dietary restrictions recommended while taking Kontracept?

A: Official regulatory documents do not specify general dietary restrictions while taking this medicine. However, specific interactions are noted with other medicines and the herbal product St. John’s Wort, which can reduce the effectiveness of Kontracept.


Q: Do you need a prescription for Kontracept, or is it available over the counter?

A: Kontracept is legally classified as a Prescription Only Medicine (POM). It is only available via a prescription from a licensed healthcare professional and is not available over the counter.


Q: Is it normal for a doctor to recommend blood tests before prescribing Kontracept?

A: Before prescribing Kontracept, your healthcare provider is required to assess your individual risk factors, especially those related to the risk of blood clots. This risk assessment typically includes checking blood pressure and may involve other tests as deemed necessary based on personal and family medical history.

How should Kontracept be stored and disposed of?

Kontracept (Gestodene/Ethinyl Estradiol) must be stored strictly according to regulatory requirements to preserve its stability.

Official Storage Conditions

The product must be stored at a temperature not exceeding 25 C and must be kept protected from light. To meet these constraints, the tablets should remain in their original packaging until use. Consistent with general safety instructions for all prescription medications, the product must be stored out of the sight and reach of children.

Disposal Instructions

When disposing of unused or expired Kontracept, the official guidance is to use a drug take-back program when available. If a take-back program is not accessible, the medicine should be mixed with an undesirable substance, placed in a sealed container, and then discarded in the household trash. The tablets must not be flushed down a toilet or disposed of in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kontracept found in:

A-Z Index: